Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines-Reference-Cited by-同舟云学术

Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines

Published:2017 Issue:1 Volume:57 Page:21-25
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Ma Chaoya¹,Horlad Hasita¹,Pan Cheng¹,Yano Hiromu¹,Ohnishi Koji¹,Fujiwara Yukio¹,Matsuoka Masao²³,Lee Aeju⁴⁵,Niidome Takuro⁶,Yamanaka Ryuya⁷,Takeya Motohiro¹,Komohara Yoshihiro¹

Affiliation:

1. Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University

2. Department of Hematology, Graduate School of Medical Sciences, Kumamoto University

3. Laboratory of Virus Control, Institute for Virus Research, Kyoto University

4. International Research Organization for Advanced Science and Technology (IROAST), Kumamoto University

5. Magnesium Research Center, Kumamoto University

6. Faculty of Advanced Science and Technology, Kumamoto University

7. Kyoto Prefectural University of Medicine, Graduate School for Health Care Science

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/57/1/57_17006/_pdf

Reference31 articles.

1. 1 Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125:3384-3391, 2015

2. 2 Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 3:21, 2015

3. 3 Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, Ascierto PA. PD-L1 expression as a potential predictive biomarker. Lancet Oncol 16:1285-1287, 2015

4. 4 Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. in press

5. 5 Eyre TA, Collins GP. Immune checkpoint inhibition in lymphoid disease. Br J Haematol 170:291-304, 2015

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model;Experimental Cell Research;2023-08

2. Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti‐breast cancer immunity: An in vitro study;Scandinavian Journal of Immunology;2023-05-24

3. Classic Hodgkin lymphoma with marked granulomatous reaction: A clinicopathologic study of 20 cases;Human Pathology;2023-04

4. Strategies for Targeting the JAK ‐ STAT Pathway in Lymphoid Malignancies;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

5. Liujunzi decoction exerts potent antitumor activity in oesophageal squamous cell carcinoma by inhibiting miR-34a/STAT3/IL-6R feedback loop, and modifies antitumor immunity;Phytomedicine;2023-03